Double Duty: Early Research Reveals how a Single Drug Delivers Twice the Impact in Fragile X

View the full article here

From the University of Rochester Medical Center Newsroom:

Like many neurological diseases, there’s a lot we don’t understand about fragile X syndrome. But, after studying the disorder for several years, Lynne Maquat’s lab knew two important things: the enzyme AKT, which plays a key role in cell growth and survival, and the quality control pathway known as NMD (nonsense-mediated mRNA decay), are both in overdrive in fragile X.

In a new study in the journal Molecular Cell, the team reveals how these two major players interact, highlighting a complex molecular dance that could inform the development of future treatments for fragile X syndrome. (click here to keep reading)

Author: Emily Boynton